5-Amino-1MQ

This study characterized methylquinolinium-scaffold small-molecule NNMT inhibitors (the chemical class to which 5-amino-1MQ belongs), demonstrating high passive/active membrane permeability and selectivity that spared other SAM-dependent methyltransferases. In cultured adipocytes, NNMT inhibition reduced the enzyme product 1-methylnicotinamide (1-MNA) while raising NAD+ and SAM levels and suppressing lipid accumulation. In diet-induced obese mice, systemic administration significantly reduced body weight and white adipose mass, decreased adipocyte size, and lowered plasma total cholesterol without altering food intake or producing observable adverse effects.

Researchers made small drug-like molecules that block NNMT, an enzyme that is overactive in fat tissue during obesity. In fat cells and in obese mice, blocking the enzyme shifted cellular chemistry in a way that reduced fat buildup. The mice lost body weight and fat mass and had lower cholesterol even though they ate the same amount of food, and no obvious side effects were seen. This is the foundational lab study behind the 5-Amino-1MQ compound class, but it was done only in mice and cells, not people.

NNMT expression is elevated in white adipose tissue and liver in obesity and diabetes. Using antisense oligonucleotide knockdown of NNMT in adipose tissue and liver of diet-induced obese mice, the authors showed increased energy expenditure and protection against weight gain. Mechanistically, NNMT knockdown raised cellular SAM and NAD+ and enhanced polyamine flux (via SSAT-driven futile cycling) and NAD+-dependent SIRT1 signaling, identifying NNMT as a regulator of histone methylation, polyamine metabolism, and cellular energy balance.

This earlier study showed why NNMT is a target for obesity. The enzyme is more active in fat and liver tissue of obese, diabetic animals. When scientists lowered its activity in obese mice, the animals burned more energy and resisted gaining weight. The work explained the biological pathway that later inhibitor drugs like 5-Amino-1MQ aim to exploit, though again this was mouse research, not human.

In diet-induced obese (DIO) mice, combining the NNMT inhibitor 5-amino-1-methylquinolinium with a switch to a low-fat diet produced greater and faster reductions in body weight and adiposity than diet change alone, approaching lean-control values. Gut microbiome analysis showed that diet switching drove most compositional shifts, but NNMTi treatment produced a distinct signature marked by decreased Erysipelatoclostridium and increased Lactobacillus abundance. Increased Parasutterella abundance correlated with adipose tissue metabolite profiles, suggesting links between specific taxa and treatment-associated metabolic changes.

This study used the actual 5-Amino-1MQ compound in obese mice and found that pairing it with a lower-calorie, low-fat diet drove faster fat and weight loss than dieting alone. It also changed the mix of gut bacteria in a distinctive way, with some potentially beneficial bacteria increasing. The findings hint that the drug's effects may involve the gut microbiome, but this remains preclinical mouse data with no human evidence.